The central GLP-1: implications for food and drug reward
about
Gut-brain peptides in corticostriatal-limbic circuitry and alcohol use disordersDegradation and Stabilization of Peptide Hormones in Human Blood SpecimensObesity: Current and potential pharmacotherapeutics and targets.Liraglutide and obesity: a review of the data so far.Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity.Activation of the GLP-1 receptors in the nucleus of the solitary tract reduces food reward behavior and targets the mesolimbic system.Hippocampal GLP-1 receptors influence food intake, meal size, and effort-based responding for food through volume transmissionIncretins and amylin: neuroendocrine communication between the gut, pancreas, and brain in control of food intake and blood glucose.PPG neurons of the lower brain stem and their role in brain GLP-1 receptor activation.Sex and estrogens alter the action of glucagon-like peptide-1 on reward.GLP-1 influences food and drug rewardSeptal Glucagon-Like Peptide 1 Receptor Expression Determines Suppression of Cocaine-Induced BehaviorGlucagon-Like Peptide-1 Receptor Activation in the Ventral Tegmental Area Decreases the Reinforcing Efficacy of Cocaine.Role of lateral septum glucagon-like peptide 1 receptors in food intakeIntestinal PPARĪ³ signalling is required for sympathetic nervous system activation in response to caloric restriction.Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity.The Obesity-Impulsivity Axis: Potential Metabolic Interventions in Chronic Psychiatric Patients.Neural integration of satiation and food reward: role of GLP-1 and orexin pathways.The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond.Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity.Lipids and obesity: Also a matter of taste?Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.Endogenous Glucagon-like Peptide-1 Receptor Signaling in the Nucleus Tractus Solitarius is Required for Food Intake Control.Protein based therapeutic delivery agents: Contemporary developments and challenges.Lateral hypothalamic GLP-1 receptors are critical for the control of food reinforcement, ingestive behavior and body weight.Hindbrain GLP-1 receptor mediation of cisplatin-induced anorexia and nausea.Exendin-4 reduces food intake via the PI3K/AKT signaling pathway in the hypothalamus.Altered Dopamine Synaptic Markers in Postmortem Brain of Obese Subjects.Neuroendocrine mechanisms that connect feeding behavior and stress.Cocaine- and amphetamine-regulated transcript: a novel regulator of energy homeostasis expressed in a subpopulation of pancreatic islet cells.Central GLP-1 receptor activation modulates cocaine-evoked phasic dopamine signaling in the nucleus accumbens core.Amylin - Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity.Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study.The Hypothalamic Glucagon-Like Peptide 1 Receptor Is Sufficient but Not Necessary for the Regulation of Energy Balance and Glucose Homeostasis in Mice.Suckling induced activation pattern in the brain of rat pups.Influences of Dietary Added Sugar Consumption on Striatal Food-Cue Reactivity and Postprandial GLP-1 Response.Vagal Interoceptive Modulation of Motivated Behavior.Chewing Stimulation Reduces Appetite Ratings and Attentional Bias toward Visual Food Stimuli in Healthy-Weight Individuals.To Do or Not to Do: Dopamine, Affordability and the Economics of Opportunity.Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats.
P2860
Q27014840-9649F39C-F74D-4FD0-B5BA-E8A7EE687C4FQ28546842-A5F17B19-0A97-4418-8430-D99C4FD89AEEQ30243992-DB689842-8F28-47CD-B76D-6AC563EF2FB2Q30924982-AC492A63-8293-43C0-8B66-EC16CC3B618EQ33830475-1A057DAA-C564-4C54-9212-775110C9591AQ35202664-3CAC4783-424E-47AB-81D4-7C4000A205FBQ35647295-8E700C48-6505-48F6-B441-5DF9356444A3Q35690970-25201159-6889-455E-847D-FC55CFBE042FQ36339320-325EBC57-35C9-45EA-9A89-C16870FB4910Q36469127-1AD5F053-1735-42B3-8239-8C1B49CC4037Q36770367-DF5B96A5-4C26-4A5B-B655-8D11B36FB555Q36821806-A31E35FA-FEFE-4367-9AD7-94E977754C4EQ36906694-7F3910C8-AC71-4A30-9846-74894143D326Q37139700-E156F8EC-31E9-4906-A2BD-62AFB5990E97Q37419913-6CE3C4A4-58BA-4468-B9B7-BE65E2525D1CQ37501257-6A75D1C3-70C1-4C91-BCBE-3F1B3DE7050EQ37637480-0F976539-8870-4B8C-9AC5-FA296E3AC06FQ38197775-46D5A9A5-2E55-42EC-B083-62A1BC6C618FQ38820260-E71DEE87-4B75-46D0-B058-6BF463685617Q38820528-5DF142CB-D00A-4BCD-8E69-1B9985833443Q38831229-2809B45D-56EC-42CC-91F9-0E8E9F556548Q39047697-C796908B-5D87-404D-9E01-9EC720E6B19BQ39249139-890D98D1-32B5-44AC-8C14-67A85B5D2A6AQ39273739-9667C36E-E676-418B-A22E-AAA49BBC82D3Q40046441-AAF2D718-DA9F-4FE1-AC77-39E69F7B83A5Q40368897-A5D7CC75-AB29-4F26-A05E-FE3A8DA3AC0FQ41191799-2A3ED23D-B183-4679-84D3-4EA6BD23BE56Q41222290-6ADA1CCC-23D1-487F-98E6-A32AD5DACA69Q42125522-B009B839-84F7-469D-A920-B015E5FEFE64Q46515724-D5A84805-FA8B-4111-8909-42ADB24BD961Q47356509-0D627BF7-A91A-4DE0-8F13-F1041A743517Q47371506-A0E22E95-ACF3-4149-BA8F-B631F7E4499AQ47386368-52CC44CA-CAC0-4622-9FF7-70208923F0E8Q48052616-6B2A6E98-D60F-4B3D-A433-571F8033F27FQ48315266-7AE998BE-7591-4A8C-BF4D-D630A0FC650EQ49673713-EF90FE89-C420-420B-B850-70D66AF0424CQ50143070-FE97C000-BD03-4699-881F-7FF7141580B0Q50298365-D9DAED05-486A-4245-AFA5-ABE3BCE9BF4BQ50300994-E554B831-7596-4C44-B9C7-7FCDE1217724Q52315993-EF18AB0E-FF73-4F69-A72D-1DF0129490F2
P2860
The central GLP-1: implications for food and drug reward
description
2013 nĆ® lÅ«n-bĆ»n
@nan
2013 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
2013 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
2013幓ć®č«ę
@ja
2013幓č«ę
@yue
2013幓č«ę
@zh-hant
2013幓č«ę
@zh-hk
2013幓č«ę
@zh-mo
2013幓č«ę
@zh-tw
2013幓č®ŗę
@wuu
name
The central GLP-1: implications for food and drug reward
@ast
The central GLP-1: implications for food and drug reward
@en
The central GLP-1: implications for food and drug reward
@en-gb
The central GLP-1: implications for food and drug reward
@nl
type
label
The central GLP-1: implications for food and drug reward
@ast
The central GLP-1: implications for food and drug reward
@en
The central GLP-1: implications for food and drug reward
@en-gb
The central GLP-1: implications for food and drug reward
@nl
prefLabel
The central GLP-1: implications for food and drug reward
@ast
The central GLP-1: implications for food and drug reward
@en
The central GLP-1: implications for food and drug reward
@en-gb
The central GLP-1: implications for food and drug reward
@nl
P2860
P356
P1476
The central GLP-1: implications for food and drug reward
@en
P2093
Karolina P Skibicka
P2860
P356
10.3389/FNINS.2013.00181
P407
P577
2013-01-01T00:00:00Z